Warning: count(): Parameter must be an array or an object that implements Countable in /home/hmc/public_html/wp-content/plugins/formcraft3/formcraft-main.php on line 1013
Thank you and congratulations for attending this educational activity.
Remember, continuous professional development is key to success and professional excellence.
In an attempt to always improve our educational provision at HMC, your feedback is very important to us as it will ensure excellent quality and better, well-structured educational activities in the future.
NCCCR_2020 Oncology Hematology Educational Round_01_12_2020
0 of 4 questions completed
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
0 of 4 questions answered correctly
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
Well done 🙂
The target cluster of differentiation for polatuzumab vedotin is:
The FDA-approved use for polatuzumab vedotin include:
The main expected adverse drug event associated with polatuzumab vedotin therapy is:
Polatuzumab use is approved as: